Benign prostatic hyperplasia medications

Marberger M, Harkaway R, de la Rosette J. Optimising the medical management of benign prostatic hyperplasia. Eur Urol 2004 45 411-419. 

Summary of Medical Treatment Options for Benign Prostatic Hyperplasia... 

Quinethazone 1169 and metolazone 1170 are used medically as diuretics, and alfazosin 1171, an cti-adreno-receptor antagonist related to prazosin is used to improve urinary flow rate in the treatment of benign prostatic hyperplasia. 

Striking evidence of the association of finasteride with male breast cancer comes from the Medical Therapy of Prostatic Symptoms (MTOPS) study, a National Institutes of Health (NIH)-sponsored study of about 3047 men that compared finasteride, doxazosin, and the combination for the treatment of benign prostatic hyperplasia. The rate of breast cancer in this trial for men taking finasteride either alone or with doxazosin was four in 1554, or nearly 200 times that of the general population one man in the finasteride + doxazosin group and three in the finasteride-alone group developed male breast cancer (74). 

Nickel JC. Long-term implications of medical therapy on benign prostatic hyperplasia end points. Urology 1998 51 Suppl A 50-7. 

Symptomatic benign prostatic hyperplasia (BPH) is a common medical problem in older men. As many as 40% of men aged 60 years or older have lower urinary tract symptoms consistent with bladder outlet obstruction. Treatment goals in the vast majority of men are to relieve bothersome symptoms that reduce quality of life. In the U.S., treatment for benign prostatic hyperplasia costs more than 2 billion per year and accounts for 1.7 million physician office visits annually (Ishani et al., 2000). 

A recent survey demonstrated that one third of men choosing nonsurgical therapy for benign prostatic hyperplasia were using herbal preparations alone or in combination with prescription medications. There is emerging evidence that several plant extracts are well tolerated and provide at least short-term improvement in urologic symptoms and flow. 

New England Journal of Medicine 345 107-114 Kirby R 1999 Benign prostatic hyperplasia. British Medical Journal 318 343-344 Klahr S, Miller S B 1998 Acute oliguria. New England Journal of Medicine 338 671-675 Lepon H, Williford W O, Barry M J et al 1996 The efficacy of terazosin, finasteride, or both in benign prostatic hjrperplasia. New England Journal of Medicine 335 533-539... 

A 53-year-old man, who had self-medicated with a saw palmetto supplement for benign prostatic hyperplasia, had profuse bleeding (estimated blood loss 2 liters) after resection of a meningioma and required 4 units of packed erythrocytes, 3 units of platelets, and 3 units of fresh frozen plasma (7). Postoperatively his bleeding time was 21 minutes (reference range 2-10 minutes), but all other coagulation tests were normal. He made an uneventful recovery. 

Vaughan ED Jr. Medical management of benign prostatic hyperplasia—are two drugs better than one N Engl J Med 2003 349 2449-2451. 

Belgium approved as prescription medication as adjunctive treatment for benign prostatic hyperplasia (enlarged prostate). 

Wilt, T. et al. "Saw Palmetto Extracts for Treatment of Benign Prostatic Hyperplasia." Journal of the American Medical Association 2S0( S) 16049, 1998. 

Lepor H, Williford WO, Barry MJ, et al. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. J Urol 1998 160 1358-1367. 

---